OLR1 and cancer: Overall, 5-, 12-, and 15-LOX-1 coexist in the human kidney but show opposite trends in the course of cancer progression, with increased 15-LOX-1 and decreased 5- and 12-LOX levels at the onset, then reversing with the progressing stage of the disease or grade of tumor [179].